BioSpace

Ono cans 2 endocannabinoid drug studies after quintuple Phase 2 failure

Ono Pharma’s ONO-1110 failed five Phase 2 trials, leading to the discontinuation of development in depression and social anxiety. Work will continue for three pain indications.

By BioSpace

1 min read
Ono cans 2 endocannabinoid drug studies after quintuple Phase 2 failure
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights